Kyowa Kirin International

First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of MF and SS.
15 April 2024
Download (329 KB)

Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases.
24 January 2024
Download (850 KB)

New Post Hoc Analysis from MAVORIC Trial Sheds Light on the Burden of Cutaneous T-Cell Lymphoma on Health-Related Quality of Life.
11 December 2023
Download (298 KB)

Kyowa Kirin Responds to NICE’s Publication of Appraisal Consultation Document for CRYSVITA® (Burosumab), for Treatment of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults.
29 November 2023
Download (224 KB)

Kyowa Kirin demonstrates commitment to real-world evidence for POTELIGEO® (mogamulizumab) at EORTC 2023.
21 September 2023
Download (346 KB)

Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration
2 August 2023
Download (211 KB)

Scottish Medicines Consortium (SMC) Enables Access to First Treatement Tackling the Underlying Cause of X-Linked Hypophosphataemia (XLH) in Adults
13 February 2023
Download (270 KB)

Grünenthal and Kyowa Kirin International announce Joint Venture Collaboration for established medicines portfolio
24 November 2022
Download (139 KB)

Kyowa Kirin Appoints Abdul Mullick, President, Kyowa Kirin International, to New Global Role as Vice Chief International Business Officer; Jeremy Morgan appointed President, Kyowa Kirin International
08 November 2022
Download (131 KB)

Kyowa Kirin receives European Commission Approval for Use of CRYSVITA®▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)
18 August 2022
Download (213 KB)

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA® ▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)
28 June 2022
Download (216 KB)

New Real World Evidence Underlines Benefits of POTELIGEO®▼ (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients
14 October 2021
Download (220 KB)

Long-term CRYSVITA® ▼ (burosumab) treatment reduces the burden of disease in adults with X-Linked Hypophosphataemia (XLH), a rare genetic metabolic bone disease
24 September 2021
Download (208 KB)

Kyowa Kirin Announces EU Approval for the Self-administration of CRYSVITA® ▼ (burosumab) to Treat X-Linked Hypophosphataemia (XLH)
19 July 2021
Download (189 KB)

Kyowa Kirin welcomes the decision that the National Institute for Health and Care Excellence will revisit their appraisal of the innovative systemic treatment, POTELIGEO® (mogamulizumab), for adults living with two forms of ultra-rare non-Hodgkin lymphoma
11 June 2021
Download (290 KB)

New Data Analysis Shows Link between Blood Involvement and Response to Treatment in Cutaneous T-cell Lymphoma (CTCL) Patients
11 June 2021
Download (216 KB)

Kyowa Kirin Receives Positive CHMP Opinion for the Self-administration of CRYSVITA® ▼ (burosumab) to Treat X-Linked Hypophosphataemia (XLH), a Rare Metabolic Bone Disorder
07 May 2021
Download (435 KB)

Kyowa Kirin responds to the National Institute for Health and Care Excellence (NICE) decision to not provide people living with certain rare blood cancers access to POTELIGEO® (mogamulizumab)
04 March 2021
Download (273 KB)

Kyowa Kirin Receives Positive CHMP Opinion for the Expanded Use of CRYSVITA® (burosumab) to Include Older Adolescents and Adults for the Treatment of X-Linked Hypophosphataemia (XLH)
24 July 2020
Download (116 KB)

Kyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency
06 January 2020
Download (84 KB)

Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)
14 February 2019
Download (226 KB)

Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™ (burosumab injection) for the Treatment of X–linked Hypophosphatemia (XLH) in Adults and Children
06 December 2018
Download (223 KB)

Kyowa Kirin Announces POTELIGEO® Receives Marketing Authorisation in Europe for the Treatment of Mycosis Fungoides and Sézary Syndrome
26 November 2018
Download (498 KB)

Kyowa Kirin Presents data at EORTC-Cutaneous Lymphoma Task Force meeting showing significantly improved Quality of Life for patients with mycosis fungoides (MF) and Sézary Syndrome (SS) on Mogamulizumab
28 September 2018
Download (370 KB)

Kyowa Kirin Announces Mogamulizumab Received Positive CHMP Opinion for the Treatment of Mycosis Fungoides and Sézary Syndrome
21 September 2018
Download (62 KB)

NICE BACKS CRYSVITA® (BUROSUMAB) FOR RARE METABOLIC BONE DISORDER, X-LINKED HYPOPHOSPHATAEMIA (XLH)
05 September 2018
Download (63 KB)

Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome
09 August 2018
Download (76 KB)

Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine
24 May 2018
Download (249 KB)

Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion for the Treatment of X-Linked Hypophosphatemia in Children
15 December 2017
Download (320 KB)

Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application
10 October 2017
Download (138 KB)

Ultragenyx and Kyowa Hakko Kirin Announce Additional Burosumab Data in X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO) at ASBMR
12 September 2017
Download (148 KB)

Kyowa Hakko Kirin and Kyowa Kirin International Announce Regulatory Updates for Burosumab in the US and EU
28 July 2017
Download (133 KB)

First Early Access Programme Initiated for Kyowa Kirin International’s Investigational Treatment for X-Linked Hypophosphatemia (XLH)
24 July 2017
Download (121 KB)

Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia
18 April 2017
Download (152 KB)

Ultragenyx and Kyowa Kirin International Announce Positive Data from Paediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia
06 April 2017
Download (368 KB)

Kyowa Kirin International announces that it is to expand its headquarters facility in Galashiels
02 February 2017
Download (309 KB)

Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency
05 January 2017
Download (639 KB)

Kyowa Hakko Kirin Announces First Patient Enrolled Global Phase 3 Study of KRN23 in Pediatric Patients with X-Linked Hypophosphatemia (XLH)
26 October 2016
Download (124 KB)

Kyowa Hakko Kirin Announces Positive Interim Data from Pediatric and Adult Phase 2 Studies of KRN23 in X-Linked Hypophosphatemia
20 September 2016
Download (643 KB)

Kyowa Hakko Kirin Announces Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia
20 September 2016
Download (517 KB)

US Food and Drug Administration Granted Breakthrough Therapy Designation for KRN23 for Pediatric X-Linked Hypophosphatemia
28 June 2016
Download (102 KB)

Kyowa Hakko Kirin Announces Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia
21 April 2016
Download (78 KB)

ProStrakan rebrands as Kyowa Kirin
18 April 2016
Download (116 KB)

ProStrakan and AstraZeneca enter into agreement for rights to Moventig® in Europe
29 February 2016
Download (237 KB)

ProStrakan completes acquisition of Archimedes
06 August 2014
Download (96 KB)

ProStrakan Agreement to Acquire Archimedes
11 July 2014
Download (82 KB)

ProStrakan Announces Board Changes
11 November 2013
Download (127 KB)

ProStrakan Announces EU Launch of Sancuso
30 September 2013
Download (76 KB)

ProStrakan Announces 3 Abstracts for Sancuso
09 July 2013
Download (155 KB)

ProStrakan Acquires Breast Cancer Product for the US
01 October 2012
Download (90 KB)

Orexo acquires US commercial rights of Abstral and ProStrakan acquires the corresponding rights in the EU and rest of the world
04 June 2012
Download (85 KB)

ProStrakan Partners with Aptalis for Rectiv in the US
09 January 2012
Download (177 KB)

FDA Approves Shared REMS for all TIRF Pain Treatments
30 December 2011
Download (37 KB)

ProStrakan Announces New Chief Executive
07 July 2011
Download (101 KB)

ProStrakan Receives FDA Approval for Rectiv for the Treatment of Moderate to Severe Pain Associated with Chronic Anal Fissures
22 June 2011
Download (220 KB)

Media Centre

Latest News

Who to Contact